3月27日,君实生物(SH688180)发布2024年年报,公司实现营业收入19.48亿元,同比增长29.67%,归母净利润为-12.81亿元,净亏损额同比缩窄43.90%。公司表示,收入的增加主要由于商业化药品销售收入同比增长。在营业收入增加的同时,公司积极落实“提质增效重回报”行动方案,持续加强各项费用管控、降低单位生产成本,并提升销售效率,同时将资源聚焦于更具潜力的研发项目,这些举措使得亏损...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.